5/12 Mannkind Q1: Nothing But Losses •The first quarter had losses of $16.3 million. •The company made more money selling bulk insulin than their inhalable drug Afrezza. •With no improvement in sales, I don't know how MannKind can stem its losses from continuing. https://seekingalpha.com/article/4072614-mannkind-corp-nothing-losses?auth_param=1vat:1chbheb:1f209c2fbcc6e4f8348f309ff84c9019&uprof=51#alt3